Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial
Document Type
Article
Publication Date
1-1-2026
Abstract
Background and objective Perioperative bleeding is common. Evidence for tranexamic acid (TXA) in urology remains limited and conflicting, and major urologic guidelines provide no recommendations. In an a priori planned analysis, we evaluated TXA among patients undergoing urologic surgery in POISE-3. Methods POISE-3 was an international randomized trial of patients undergoing surgery with bleeding and cardiovascular risk factors. Participants received TXA (1 g intravenous bolus at surgery start and end) or placebo. The primary efficacy outcome was a 30-day bleeding composite (life-threatening/major/critical organ), and the primary safety outcome was a 30-day thrombosis composite (myocardial injury after noncardiac surgery [MINS], nonhemorrhagic stroke, peripheral arterial thrombosis, or symptomatic proximal venous thromboembolism [VTE]). Key findings and limitations Among 1124 urologic participants (556 TXA and 568 placebo), 489 had laparoscopic/robotic, 360 open, 244 transurethral, and 31 percutaneous surgery. The composite bleeding outcome occurred in 45 (8.1%) with TXA and in 62 (10.9%) with placebo (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.50–1.07). Major bleeding occurred in 34 (6.1%) with TXA and in 54 (9.5%) with placebo (HR = 0.63, 95% CI = 0.41–0.97). The composite safety outcome occurred in 67 (12.1%) with TXA and in 62 (10.9%) with placebo (HR = 1.12, 95% CI = 0.79–1.58; MINS: 62 vs 58; strokes: 2 vs 2; VTEs: 3 vs 3). We identified no interactions by surgical approach, cancer status, or recent antithrombotic usage. Patient-important thrombotic events were few, limiting precision for stroke and VTE estimates. Conclusions and clinical implications TXA reduced major bleeding and supports perioperative use in urologic surgery, especially when the bleeding risk is high.
Keywords
Antifibrinolytic agents, Blood loss, Blood transfusion, Cystectomy, Nephrectomy, Nephrolithotomy, Percutaneous, Prostatectomy, Stroke, Thrombosis, Transurethral resection of prostate
Publication Title
European Urology
ISSN
03022838
DOI
10.1016/j.eururo.2026.03.019
Recommended Citation
Tikkinen, Kari A.O.; Marcucci, Maura; Halme, Alex L.E.; Ofori, Sandra N.; Borges, Flavia K.; Kanstrup, Charlotte T.B.; Park, Lily J.; Tondroanamag, Farhad; Kilpeläinen, Tuomas P.; Tornberg, Sara V.; Painter, Thomas W.; Conen, David; Lomivorotov, Vladimir; Sessler, Daniel I.; Chan, Matthew T.V.; Martinez-Zapata, Maria Jose; Wang, Chew Y.; and Xavier, Denis B., "Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial" (2026). Research Publications (2026 to 2030). 2125.
https://knova.um.edu.my/research_publications_2026_2030/2125